In a move likely to cause sharp price reductions for cholesterol-lowering drugs, the FDA gave approval for six more companies to launch generic copies of Merck’s Zocor (simvastatin). Analysts say the ...

Merck is implementing an aggressive price control plan for cholesterol treatment Zocor (simvastatin) to hang on to market share following the drug’s loss of patent protection Friday.A spokesman from ...

Who wouldn't love to find a drug to help prevent or at least delay the onset of Alzheimer's disease? It turns out that one may already exist. Dr. Benjamin Wolozin, professor of pharmacology at Boston ...

I'm taking the cholesterol-lowering drug Lipitor and am considering switching to the generic form of Zocor (simvastatin) because it's cheaper and my insurance doesn't have a prescription-drug program.

High doses of the cholesterol-lowering drug Lipitor were no better at preventing major heart problems than regular doses of rival Zocor, according to the latest study on efforts to aggressively treat ...

Highest approved dose of cholesterol-lowering medication could cause harm to muscles The U.S. Food and Drug Administration today warned patients and healthcare providers about the potential for ...

Aetna Inc. said Thursday that it would buy discounted copies of the cholesterol drug Zocor from Teva Pharmaceutical Industries Ltd. rather than accept an offer from Merck & Co. to sell its branded ...

(CBS/AP) Is Zocor dangerous? The FDA is warning that high doses of the blockbuster cholesterol drug can harm muscles and cause potentially deadly kidney damage. It's added new warnings to Zocor in an ...

In 2009, pharmacists filled over 200 million prescriptions for statins, the drug that’s thought to prevent heart attacks and strokes. And, manufacturers of the drug, more commonly known as Zocor, ...

FDA review finds increased risk of muscle damage, kidney failure. June 9, 2011 — -- The U.S. Food and Drug Administration has recommended limiting high doses of a widely prescribed ...

Whitehouse Station, NJ - Merck's blockbuster cholesterol-lowering agent, Zocor (simvastatin), loses its US patent protection tomorrow, when the first generic competitors will appear. This move is ...

Second-quarter financial results from U.S. pharmaceutical companies gave an early glimpse into life after Zocor, the blockbuster cholesterol drug from Merck that lost patent protection with just a ...